The extraordinary speed of antibiotic resistance acquisition of Staphylococcus aureus, associated with the severity of staphylococcal infections, dictates the urgent need of a vaccine against this deadly pathogen. However, although several vaccine candidates have been proposed and some of them have been tested in clinical trials using both active and passive immunization modalities [1] , an effective vaccine is still missing.
In an attempt to develop an S. aureus vaccine, we have been applying a reverse vaccinology approach, mainly based on in silico screening and proteomics, to select surface-exposed proteins. As reported in this work, FhuD2 (ferric hydroxamate uptake) is one of the proteins identified through our screening. FhuD2 was first discovered as a ferric hydroxamate siderophore binding protein that mediates iron uptake through a dedicated ATP binding cassette (ABC) transporter [2] . Production of hydroxamates by S. aureus has not yet to our knowledge been demonstrated, and it is assumed that FhuD2 binds xeno hydroxamates (produced by other microorganisms) such as ferrichrome, coprogen, and aerobactin, for which the protein was shown to have high affinity in vitro [2] . Because iron availability is known to be a key element for S. aureus pathogenesis [3] [4] [5] , and because little was known about the role played by FhuD2 and the hydroxamate-uptake system in infective processes, we explored the relevance of this protein in S. aureus pathogenesis and investigated its immunoprotective properties in mouse models of infection.
MATERIALS AND METHODS
Bacterial Strains, Media, and Growth Conditions S. aureus strains were cultured in tryptic soy agar (TSA) or broth (TSB) and iron-depleted, RPMI1640 medium containing 0.6 mM 2.2-dipyridyl (Sigma Chemicals, St. Louis, Missouri), or iron-replete conditions (RPMI1640 complemented with 0.2 mM FeCl 3 ) at 37°C. Strains are listed in Supplementary material, Table S1 .
Antigen Identification by In Silico and Mass Spectrometry Analysis
In silico antigen identification was performed analyzing the S. aureus NCTC8325 genome by several bioinformatic algorithms as described elsewhere [6] [7] [8] . Surfome analysis of S. aureus live cells was performed as described elsewhere [9, 10] , with minor modifications. Briefly, S. aureus strain Newman was plated on TSA containing 5% sheep blood and grown overnight. Bacterial colonies were then grown in TSB at 37°C under agitation (250 revolutions per minute [rpm] ) in the presence of 5% CO 2 to OD600 nm = 0.4. Bacterial pellets were then suspended in 5 mM ammonium bicarbonate and incubated at 37°C with 20 µg of trypsin. Bacterial cells were then spun down and supernatants analyzed by nanoLC/MS/MS followed by database search using Mascot (www.matrixscience. com).
Cloning and Purification of FhuD2
The fhuD2 was amplified by polymerase chain reaction (PCR) from S. aureus NCTC8325 strain and cloned as N-terminal 6-histidine-tagged (His-tag) or tagless constructs. His-tag FhuD2 was purified by immobilized metal ion affinity chromatography purification using a nickel-activated chelating sepharose column (GE Healthcare His-trap HP). Tagless FhuD2 was purified by cation exchange chromatography using a HiTrap SP Sepharose FF column. See Supplementary material for more details.
Generation and Complementation of fhuD2 Mutants
A mutant with an insertional lesion of the bursa aurealis minitrasposon in the fhuD2 gene of S. aureus Newman was provided by Dr Dominique Missiakas, University of Chicago. The mutational lesion was transduced into a wild-type S. aureus Newman generating strain fhuD2::ermC, and the insertion was verified by DNA sequencing. For plasmid complementation, full length fhuD2 was PCR amplified from S. aureus Newman strain and cloned into NotI-BglII sites of plasmid pAM-401 [11] . The resulting plasmid pfhuD2 was transformed into the fhuD2::ermC strain.
FhuD2 Expression Analysis
The expression of fhuD2 was evaluated in vitro, by Western blot and immunofluorescence confocal microscopy, as well as in vivo, by quantitative real-time PCR (qRT-PCR). For Western blot analysis, equal amounts of total cell proteins from each strain were separated on SDS-PAGE and transferred to nitrocellulose membranes. Detection of FhuD2 on the bacterial surface by immunofluorescence confocal microscopy was performed using bacteria grown in iron limited conditions. S. aureus cells were fixed and stained with αFhuD2 antibody and biotinylated wheat germ agglutinin (WGA). Following primary staining, cells were incubated with Alexafluor-568 goat anti-rabbit immunoglobulin G (IgG) (H + L) secondary antibody, and Alexafluor-488 conjugated streptavidin. To measure expression of fhuD2 gene in infected mice, kidneys were homogenized and bacteria were separated from eukaryotic cells by slow-speed centrifugation. RNA was extracted and reverse transcribed to complementary DNA and amplified by RT-PCR. The relative expression of fhuD2 in kidney tissue was measured and calibrated against the expression of the gene in bacteria grown in the initial inoculum, that is, TSB. Expression level of the gene was then normalized with that of 16 s ribosomal RNA (rRNA). The 16-s rRNA gene was found to be consistently expressed at different cultivation time points [12] . See Supplementary material for further details.
Ethics Statement
Mice and rabbits were monitored daily and killed at the appearance of humane endpoints, in accordance with Novartis Animal Welfare Policies and Italian law. Experimental protocols were reviewed and approved by the Italian National Institute of health, ISS (Istituto Superiore di Sanità), with the protocol number (136/2010-B) for mouse studies and (201103) for rabbit studies.
Active Immunization
Five-week-old CD1 mice were immunized intraperitoneally with a prime-booster injection of 20 µg purified recombinant FhuD2 adsorbed to aluminum hydroxide adjuvant (alum, 2 mg/mL) in 14′ day interval. Control mice received equal amounts of phosphate-buffered saline (PBS) and alum adjuvant. Animals were bled immediately prior to the first immunization and 23 days thereafter, and serum samples were examined for IgG antibodies directed against purified FhuD2 using the Luminex technology (see Supplementary material for further details).
Passive Immunization
New Zealand rabbits were immunized by intradermal injection with 50 µg of FhuD2 adsorbed to aluminum hydroxide (2 mg/mL) on days 0, 21, and 35. Rabbit immune serum samples (150 µL) were injected into the tail vein of 8-week-old CD1 mice 24 hours prior to challenge with S. aureus infection. Control mice were injected with the same volume of serum from rabbits that had been immunized with PBS and aluminum hydroxide.
Renal Abscess Model
Immunized animals were challenged on day 24 by intravenous injection of a sublethal dose of S. aureus (approximately 2-6 × 10 7 CFU, specific inoculum varied depending on the challenge strain). On day 28, mice were killed, and kidneys were removed and homogenized in 1% Triton X-100 and plated on agar media in triplicate for determination of colony forming units (CFU). Kidneys were also processed for histopathology as described below. See Supplementary material for further details.
Sepsis Model
Immunized animals were challenged on day 24 by intraperitoneal injection of a lethal dose of S. CFU of S. aureus (specific inoculum varied depending on the challenge strain).
Histopathology
Mouse kidneys were cut in 2 equal halves along the sagittal plane, then fixed in 4% buffered formaldehyde, and processed for paraffin embedding. Then 4-µm sections were cut from each kidney and stained with hematoxylin and eosin (HE).
Images of each HE-stained kidney were acquired by Mirax Scan 150 slide scanner equipped with 40× lens. Two sections for each kidney were examined, and the one with the most abundant abscesses was used for quantification. The number of abscesses was counted, and the total area of abscessualization, including suppurative infiltrate areas, was quantified in each kidney using the Mirax viewer software. The area of abscesses for a given section was calculated as the percent of the area of the section covered by the abscesses.
Opsonophagocytosis Killing Assay
Human promyelocytic leukemia cells HL-60 (ATCC CCL240) were maintained in enriched medium and differentiated into phagocytes using 0. ). Staphylococcal strains grown overnight in TSB were washed once in PBS, then incubated with serum (75 000 CFU/well) at 4°C for 20 minutes. Differentiated HL-60 cells were distributed at 3.7 × 10 6 per well (HL-60:bacteria ratio, 50:1) and rabbit complement was added at 10% final concentration. Plates were then incubated at 37°C for 1 hour, under agitation at 600 rpm and samples were plated onto TSA plates for CFU counts determination.
FhuD2 Inhibition Assay
S. aureus Newman was grown under iron-depleted conditions in RPMI 1640 + 0.6 mM 2.2-dipyridyl (DIP). Approximately 10 4 CFU inoculated in the fresh medium with and without 25 µg/mL affinity purified antibodies against FhuD2 or Hla (Hemolysin). When siderophores were used, 0.1 mM coprogen or ferrichrome was added in the media. Tubes were incubated overnight at 37°C, and then CFUs were determined.
Statistical Analysis
At least 2 independent experiments, run under the same conditions, were performed for all studies. 
RESULTS

In Silico Prediction and Mass Spectrometry Identification of FhuD2
The ferric hydroxamate-binding lipoprotein FhuD2 was identified as a putative vaccine antigen during analysis of the S. aureus NCTC8325 genome by several bioinformatic algorithms as described elsewhere [6] [7] [8] . fhuD2 has a typical prolipoprotein signal peptide with a predicted cleavage site of 15 LAAC 18 ( Figure 1A ). Upstream to the coding region, a promoter and a Fur regulator binding sequence spanning nucleotides −28 to −10 was also identified. Indeed, we found that the gene is up-regulated in iron-depleted culture conditions by qRT-PCR (data not shown). Analysis of 60 genomes available in public databases indicated that fhuD2 is in the core genome of S. aureus and is highly conserved among different strains. Figure 1B ; Supplementary material, Table S1 ). In parallel with the in silico analysis, we performed a mass spectrometry (MS)-based study of the staphylococcal surface proteins. Exponentially growing S. aureus Newman cells were collected and treated with trypsin in order to shave the bacterial surface and generate peptides from protein domains exposed to the extracellular milieu (the so-called surfome) [10] . The surfome of S. aureus Newman was analyzed by nanoLC/MS/MS, and FhuD2 was identified with 2 peptides through a database search against the whole S. aureus proteome ( Figure 1A ). These results indicate that FhuD2 is exposed on the S. aureus surface and, hence, potentially visible by the host immune system and is accessible to antibodies.
Disruption of fhuD2 Impairs Ferric-Hydroxamate Uptake
To perform functional studies on FhuD2, we isolated a knockout mutant from the Phoenix library [13] containing a transposon inserted in the fhuD2 gene, which was transduced into S. aureus Newman. The resultant mutant strain (fhuD2:: ermC) was completely impaired in the expression of the protein (Figure 2A ). The fhuD2::ermC did not show any growth defect in rich TSB medium. In contrast, as previously demonstrated [2] , it grew significantly slower than the wildtype strain S. aureus Newman, when the only source of iron was provided by coprogen, a xeno siderophore highly specific to FhuD2. On the other hand, when the medium was supplemented with FeCl 3, no significant difference in growth rate was observed with respect to the wild type ( Figure 2B ). The complemented strain fhuD2::ermC-pfhuD2, which expresses the protein at levels comparable to the parental strain (Figure 2A ), showed growth properties identical to the wildtype strain in all culture conditions.
FhuD2 Has a Punctate Localization on the Bacterial Cell Surface
We also investigated the localization of FhuD2 on the surface of the pathogen. S. aureus cells cultured under iron-limiting conditions were stained with anti-FhuD2 antibodies and imaged by confocal microscopy. Nonspecific binding of antibodies to Protein A (SpA) was decreased by growing the bacteria to stationary phase, when SpA expression is repressed [14, 15] . Indeed, nonstaphylococcal IgG against Neisseria meningitidis NadA protein [16] did not stain the cells (data not shown). As shown in Figure 3 , FhuD2 antibodies bound at a few spots on the bacterial surface. The spots were quite defined and the protein was never found to be evenly distributed on the cells. As expected, FhuD2 antibodies did not bind to the mutant strain fhuD2::ermC.
FhuD2 Is Required for Bacterial Proliferation in vivo and Is UpRregulated in Bacteria Recovered From Infected Renal Tissues
Because iron is a key limiting element for bacterial pathogens in establishing invasive infections, we asked whether fhuD2 inactivation could affect bacterial growth/proliferation in vivo. CD1 mice were infected intravenously with S. aureus Newman, Newman fhuD2::ermC and Newman fhuD2::ermCpfhuD2 strains and CFU counts from blood and kidneys were measured, at 3 hours and 4 days after infection, respectively. As shown in Figure 4 , the number of bacteria recovered from mice infected with Newman fhuD2::ermC was approximately 1 Log lower than the wild type and the complemented strains.
To further explore the importance of fhuD2 in staphylococcal pathogenesis, we investigated whether the gene was upregulated in bacteria recovered from infected animals. Total Figure 1 . fhuD2 was selected by a combined approach of in silico screen and mass spectrometry (MS)-based surfome analysis. A, Peptides identified by MS, as well as the prolipoprotein signal peptide with predicted cleavage site of 15 LAAC 18 , are highlighted within the protein sequence. B, FhuD2 expression is consistent throughout epidemiologically relevant strains. The strain Newman was selected as a reference laboratory strain. LAC is a community-acquired methicillin resistant strain (CA-MRSA) of the USA300 lineage. This clone has the unique capacity to spread easily and sustainably among humans, causing invasive staphylococcal infections in both community and hospital settings. Strain Staph19 is a ST-80 clone, which is emerging in Europe (the "European clone"), and one of the most widespread CA-MRSA clones. Strain Mu50, USA100 lineage, is a methicillin and vancomycinresistant hospital-acquired strain. MW2 is a CA-MRSA, USA400 lineage. See Supplementary material, Table S1 for further information about the strains. Serum raised against FhuD2 recognized the protein at the expected molecular weight (approximately 32 kDa). Figure 2 . Growth rate of the Staphylococcus aureus Newman wild type, fhuD2::ermC and fhuD2::ermC-pfhuD2 strains, in iron deplete/ replete conditions and in the presence of coprogen. A, The mutant strain fhuD2::ermC is impaired in the expression of the protein, whereas FhuD2 expression in the complemented strain fhuD2::ermC-pfhuD2 is comparable to S. aureus Newman wild type. B, RPMI medium supplemented with 0.1 mM coprogen was inoculated with S. aureus Newman wild type, fhuD2::ermC and fhuD2::ermC-pfhuD2 at OD = 0.05 and growth rate was monitored every 60 min for 4 h. Coprogen significantly increased growth rate of the wild type and fhuD2::ermC-pfhuD2 strains but not that of the fhuD2::ermC strain.
RNA was extracted from kidneys of CD1 mice infected with S. aureus strain Newman and the level of fhuD2 expression was measured by qRT-PCR. Expression of the gene in infected renal tissues was compared to that observed with bacteria recovered from the TSB culture used to infect the mice. The level of expression was normalized to 16S ribosomal RNA which was expressed at comparable levels between the two samples (RNA from the TSB culture vs RNA from infected kidneys). The fhuD2 RNA was found to be 7-fold more abundant in renal tissues than in TSB culture. Overall, these data suggest that FhuD2 plays a role in S. aureus survival in blood, systemic dissemination, and abscess formation.
FhuD2 Vaccination Protects Mice Against the Challenge With S. aureus Clinical Isolates
Having demonstrated that FhuD2 is involved in S. aureus pathogenesis, we then asked whether FhuD2 immunization could confer protection in mouse models. Protective efficacy of FhuD2 was tested in 2 models of S. aureus infection, the sepsis and the renal abscess models. In the sepsis model, mice were challenged intraperitoneally on day 24 with a lethal injection of a bacterial suspension of Newman (ST-254), MW2 (USA400), and Staph19 (ST-80) strains. After the challenge, survival was monitored for 14 days. FhuD2 vaccination significantly protected mice from the lethal challenge with all three strains (2 independent experiments for each challenge strain with a total of 26-60 mice per group; Figure 5A ). In particular, the vaccine increased the median survival time of mice challenged with MW2, Staph19, and Newman from 6, 1, and 1 days to 15, 10.5, and 7.5 days, respectively ( Figure 5A ). However, the number of surviving mice at day 15 was only moderately increased.
In the abscess model, mice were infected intravenously with sublethal inocula of S. aureus Newman, MW2, Staph19, LAC, and the VISA Mu50. Four days after infection, kidneys of sham-immunized mice harbored typical bacterial abscesses with a central population of staphylococci (staphylococcal abscess community [SAC] ), surrounded by a layer of eosinophilic, amorphous material (the pseudocapsule), and a large cuff of polymorphonuclear leukocytes [17] , (Figure 5B-D) . In Figure 3 . FhuD2 has a discrete, punctate localization on the bacterial cell surface. Staphylococcus aureus Newman wild type and fhuD2::ermC strains were stained with biotinylated wheat germ agglutinin (WGA) and with anti-FhuD2 immunoglobulin (IgG). Alexafluor-488 conjugated streptavidin (green) and alexafluor-568 goat anti-rabbit IgG secondary antibody (red), were used respectively against WGA and the FhuD2 IgG. A and C, FhuD2 is localized at discrete, punctate sites on the surface of S. aureus Newman as well as on the fhuD2::ermC-pfhuD2 variant. B, fhuD2::ermC is not stained by the anti FhuD2 IgG. Scale bar: 1 µm. Figure 4 . fhuD2::ermC strain is impaired in the initial phases of abscess formation. CD1 mice were infected intravenously with Staphylococcus aureus Newman wild-type strain, the mutant fhuD2::ermC or the complemented strain fhuD2::ermC-pfhuD2 (N = 32, 2 separate experiments). A and B, The fhuD2::ermC strain showed fewer colony-forming unit (CFU) counts in the mouse blood 3 h after infection (mice grouped below the dashed line had undetectable CFU counts), as well as in kidneys 4 d after infection, as compared to the wild type and the complemented strains. Statistical analysis was performed by Mann-Whitney U test. Dashed line indicates the lower limit of CFU detection.
this model, FhuD2 vaccination induced significant reduction of bacterial burden in the kidneys of mice, ranging from 1.02 to 2.06 Logs CFU/mL. Mice immunized with FhuD2 also showed a remarkable reduction of the area and number of abscesses as compared to sham-immunized animals ( Figure 5E and 5F). Histological analysis of the kidneys showed numerous large abscesses in sham-immunized mice, whereas in the kidneys of mice immunized with FhuD2, the number and the Figure 5 . Protective efficacy of FhuD2 vaccination in the sepsis and abscess models. A, In the sepsis model, mice were challenged respectively with the strains MW2, Staph19 and Newman (N = 26-60 per group, at least two separate experiments). Dotted lines indicate median survival rate, which was respectively, 15, 10.5 and 7.5 d for vaccinated groups. Statistical analysis was performed by Gehan-Breslow-Wilcoxon test. B-F, Hematoxylin-eosin staining of kidney sections of S. aureus-infected mice. Mice (N = 32 per group) were immunized with alum alone (B-D ) or with FhuD2 (E ) and then challenged with S. aureus Newman. Four days after infection, kidneys were fixed, thin-sectioned, hematoxylin-eosin stained, and imaged. Representative images, ie, having abscess areas and number close to the geometric mean for the group, are shown. Staphylococcal abscess community (SAC) are indicated by white arrows, whereas the surrounding infiltrating polymorphonuclear leukocytes (PMNs) are indicated by grey arrows. C, Magnified abscess (from the circled area in B); D, magnified SAC (from the circled area in C). F, Mice (N = 16-32 per group, at least two separate experiments) were immunized with alum alone (control) or with FhuD2 and then challenged with the indicated strains of S. aureus. Renal CFU counts and morphometric analysis of the abscesses. Statistical analysis was performed by Mann-Whitney U test.
size of abscesses were either significantly reduced or showed a good trend toward reduction.
FhuD2 Vaccination Generates Functional Antibodies
CD1 mice immunized intraperitoneally with FhuD2 formulated with aluminum-hydroxide generated significant IgG titers (geometric mean titers ± SEM = 190 ± 92). To evaluate whether protection by FhuD2 vaccination was associated with functional antibodies, we performed both in vitro opsonophagocytosis assays and passive immunization experiments. Serum samples from FhuD2-vaccinated mice were analyzed for the ability to induce opsonophagocytic killing of staphylococci by differentiated HL-60 cells in the presence of rabbit complement. When complement was present, HL-60 cells killed 34% of wild-type Newman cells in the presence of anti-FhuD2 serum, and only 5% with preimmune serum and serum from animals immunized with alum alone ( Figure 6A ). The specificity of antiFhuD2 serum in inducing phagocytosis was further confirmed by testing its killing activity on Newman fhuD2::ermC strain. As expected, no killing was observed.
In order to demonstrate that protection elicited by FhuD2 was at least partially mediated by the humoral response, antiFhuD2 rabbit serum was passively transferred to mice which were subsequently challenged according to the abscess model protocol. As shown in Figure 6B , the serum reduced CFU counts in the mouse kidneys by approximately 2 Logs.
We then asked if anti-FhuD2 antibodies could also inhibit FhuD2-mediated iron uptake. S. aureus Newman wild-type and fhuD2::ermC strains were grown in iron-depleted media supplemented with coprogen, a siderophore specific to FhuD2, in the presence of FhuD2-affinity purified antibodies ( Figure 6C ). FhuD2 antibodies significantly inhibited growth of the wild-type strain, whereas the mutant was only slightly affected. No significant inhibition was observed with affinity purified Hla antibodies used as negative control or when the experiment was performed with iron-rich media (data not shown). In addition, the same experiment was performed using iron-depleted media supplemented with ferrichrome, another siderophore known to bind to FhuD2 [2] . As expected, FhuD2 antibodies had a smaller bacterial growth inhibition effect on S. aureus Newman in these conditions (0.5 Log CFU/mL reduction vs control, P = .0044). Indeed, ferrichrome is not specific to FhuD2 and can also serve as siderophore for FhuD1, another ferric-hydroxamate binding protein expressed by S. aureus [2] . Therefore, these data suggest that anti-FhuD2 antibodies are able to decrease the growth rate of the bacterium by blocking FhuD2 siderophore uptake.
CONCLUSIONS
Iron is an essential nutrient for staphylococcal growth. The role of FhuD2 in mediating iron uptake through ferrichydroxamate siderophores has been previously demonstrated [2] . Herein we demonstrate that the protein is expressed by clinical isolates of S. aureus. Interestingly, the protein was found to be localized in punctate assembly sites on the surface Figure 6 . Humoral immunity against FhuD2 plays multiple protective functions. A, Antibodies against FhuD2 mediate S. aureus opsonophagocytosis. Mouse serum against FhuD2, rabbit complement, HL-60, and the S. aureus strain Newman were incubated for 1 h and plated on TSA for CFU counting. Percent killing was calculated as the ratio between the percent killing achieved with and without serum. No bacterial killing was observed in the absence of complement, with control serum (Alum) or with the fhuD2::ermC strain, showing the specificity of the FhuD2 antiserum in mediating opsonophagocytic killing of the pathogen. Error bars represent standard deviation. Statistical analysis was performed by paired t test. B, Passive transfer of FhuD2 rabbit antiserum confers protection against S. aureus abscess formation. 150 µL of experimental mock (serum of rabbits immunized with Alum) or rabbit serum against FhuD2 (607 µg/mL) were injected into the tail vain of CD1 mice (N = 32, 2 separate experiments) and 24 h later animals were infected intravenously with S. aureus Newman. Bacterial load was determined in the kidneys of animals that had been sacrificed four days following infection. Dashed line indicates the lower limit of CFU detection. C, Antibodies against FhuD2 inhibit coprogen uptake and decrease S. aureus growth rate in iron-depleted conditions. Bacteria were grown overnight (starting inoculum 10 4 CFU) in RPMI + dipyridyl medium, with or without coprogen 0.1 mM, and containing either: 0.1 mM glycine as a negative control (glycine was used to suspend the antibodies), 25 µg/mL of affinity purified FhuD2 IgG or 25 µg/mL of affinity purified Hla IgG. Statistical analysis was performed by Mann-Whitney U test.
of the bacterium. This kind of protein localization on the surface of S. aureus was previously reported for LPXTGcontaining proteins but it has never to our knowledge been observed for lipoproteins thus far [18] . This observation suggests the existence of mechanisms governing surface distribution of staphylococcal lipoproteins, which deserves further investigation.
Cheng and coworkers recently proposed a model in which abscess formation, in S. aureus-infected mice, occurs through several steps, starting from blood survival and dissemination into the organs of the bacterium, to colonization of tissues and abscess growth [17] . Deletion of fhuD2 caused a dramatic reduction of staphylococcal load both in blood and in kidneys of infected mice, indicating that the protein is required at the initial phases of the disease progression according to the aforementioned model.
Production of hydroxamates by S. aureus has not yet been demonstrated. Therefore, it was assumed that the main role of FhuD2 is at the level of colonization of epithelial surfaces where other species can provide hydroxamate siderophores [19] . Indeed, analysis of the staphylococcal genome did not reveal any specific signature for the presence of biosynthetic genes for hydroxamate siderophores. To understand how FhuD2 retrieves iron in blood and during invasive infection, we are investigating whether the protein itself, or its siderophores-bound form, are able to interact with iron binding proteins produced by the host such as transferrin, lactoferrin and hemoglobin or with siderophores released by S. aureus such as staphyloferrin A and B. The role of the hydroxamate-uptake systems in bacterial pathogenic processes has so far been poorly investigated and our data, for the first time to our knowledge, indicate their importance during staphylococcal invasive infections and thus establish FhuD2 as an important virulence factor.
FhuD2 vaccination was shown to generate protection against S. aureus infection in 2 mouse models. Protection appears to be at least partially associated to functional antibodies, which were shown to mediate opsonophagocytosis of the bacterium, to protect mice against the infection in passive transfer experiments, and to inhibit pathogen growth likely by blocking the siderophore-uptake properties of FhuD2.
These data make FhuD2 a promising vaccine candidate to be tested in humans. However, as previously shown by other authors, antigen combinations can confer greater protection than single antigens [20, 21] . Furthermore, a vaccine based on IsdB, another staphylococcal surface antigen involved in iron uptake, which was shown to be protective in animal models, recently failed in Phase II/III clinical trials [22] [23] [24] . Therefore, it is likely that to generate a vaccine that efficiently protects humans from S. aureus infections, FhuD2 will have to be included in multicomponent vaccines comprising toxoids and antigens involved in later stages of the pathogenesis. Finally, we believe that cell-mediated immunity likely represents another protective element that should be considered in the development of novel S. aureus vaccines.
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